BioSante Pharmaceuticals, Inc. (BPAX)

[Snomm]

MARKET TALK: BioSante Pharma In Freefall After Test Results
Last update: 12/15/2011 7:47:23 AM
7:47 (Dow Jones) Shares of BioSante Pharmaceuticals (BPAX) drop over 70% premarket after the company reported disappointing clinical test results for its female sexual dysfunction drug LibiGel which failed to perform significantly better than a placebo. Oppenheimer drops coverage, Roth Capital cuts to neutral valuing the company at 65 cents a share without LibiGel, while Leerink Swann and Rodman & Renshaw both lower shares to market perform. BPAX down 72% at 58 cents. ([e-mail])
Call us at [phone] or email [e-mail]
(END) Dow Jones Newswires
December 15, 2011 07:47 ET (12:47 GMT)


Saw this and was intrigued that the stock was valued at 65 cents per share WITHOUT the LibiGel, yet it has hit a low in the mid 40's. Just crazy selling and panic apparently.
Big investors will come...get what you can at whatever price you can for now :)